MCID: NDL013
MIFTS: 47

Nodular Regenerative Hyperplasia

Categories: Liver diseases, Rare diseases

Aliases & Classifications for Nodular Regenerative Hyperplasia

MalaCards integrated aliases for Nodular Regenerative Hyperplasia:

Name: Nodular Regenerative Hyperplasia 52 71
Nodular Regenerative Hyperplasia of the Liver 52 58
Non-Cirrhotic Nodulation 52 58
Non-Cirrhotic Nodular Transformation 52
Miliary Hepatocellular Adenomatosis 52
Non-Cirrhotic Portal Hypertension 52
Nodular Hyperplasia 71

Characteristics:

Orphanet epidemiological data:

58
nodular regenerative hyperplasia of the liver
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

ICD10 via Orphanet 33 K76.8
Orphanet 58 ORPHA48372
SNOMED-CT via HPO 68 34742003
UMLS 71 C0020510 C4048264

Summaries for Nodular Regenerative Hyperplasia

NIH Rare Diseases : 52 Nodular regenerative hyperplasia (NRH) is a rare liver disease in which normal liver tissue transforms into multiple, small clusters (nodules) of replicating liver cells (regenerating hepatocytes). It can develop in people of all ages but is more common in older adults. NRH often does not cause signs or symptoms (so is likely underdiagnosed), but in some people, it leads to a type of portal hypertension called non-cirrhotic portal hypertension (NCPH). NCPH refers to abnormally high blood pressure in the portal vein (the vein that carries blood from the intestine to the liver) that is not caused by cirrhosis (scarring of liver tissue that impairs its function). NCPH typically is less severe than portal hypertension caused by cirrhosis. Symptoms of portal hypertension may include fatigue, edema , itching, jaundice , and abdominal discomfort or swelling due to fluid build-up (ascites ). Complications that may develop include bleeding esophageal varices and an enlarged and overactive spleen (hypersplenism ). Liver function in most people with NRH remains normal (even in those who develop NCPH), and liver failure in people with NRH and NCPH is rare. The cause of NRH is not well-understood. It is thought that the liver's blood vessels somehow become damaged or inflamed, impairing blood flow to parts of the liver. This in turn may cause cells in adjacent parts to "overcompensate" and replicate more than they should, leading to NRH. While some people with NRH have no known underlying health problems, NRH is often associated with rheumatic , autoimmune, hematologic (blood-related), and myeloproliferativ e disorders; chronic or recurrent infections; immune deficiency; or exposure to certain medications or toxins . NRH may be diagnosed based on signs and symptoms (when present), liver function tests (which usually are normal), medical history (including drug or toxin exposure), imaging studies, and liver biopsy (to rule out cirrhosis). Treatment for people with NCPH may involve starting medications to prevent or treat bleeding esophageal varices, stopping medications associated with NCPH, and treating underlying health conditions associated with NCPH. The long-term outlook for people with NRH depends on whether an underlying health problem is present and whether NCPH and its complications develop (which cannot be predicted). A small proportion of people eventually need a liver transplant .

MalaCards based summary : Nodular Regenerative Hyperplasia, also known as nodular regenerative hyperplasia of the liver, is related to hepatic veno-occlusive disease and budd-chiari syndrome. An important gene associated with Nodular Regenerative Hyperplasia is NOTCH1 (Notch Receptor 1), and among its related pathways/superpathways are Th17 cell differentiation and Notch Signaling Pathway (WikiPathways). The drugs Caffeine and Calcium have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and bone marrow, and related phenotypes are portal hypertension and abnormality of the hepatic vasculature

Wikipedia : 74 Nodular regenerative hyperplasia is a form of liver hyperplasia associated with portal hypertension.... more...

Related Diseases for Nodular Regenerative Hyperplasia

Diseases related to Nodular Regenerative Hyperplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 252)
# Related Disease Score Top Affiliating Genes
1 hepatic veno-occlusive disease 30.3 TPMT F3
2 budd-chiari syndrome 30.0 GFER F3
3 adams-oliver syndrome 29.6 NOTCH2 NOTCH1 JAG1
4 alagille syndrome 1 29.4 NOTCH2 NOTCH1 JAG1
5 portal hypertension 11.0
6 varicose veins 10.7
7 splenomegaly 10.6
8 esophageal varix 10.6
9 liver cirrhosis 10.6
10 autoimmune disease 10.6
11 felty syndrome 10.6
12 inflammatory bowel disease 10.5
13 primary biliary cirrhosis 10.5
14 cholestasis 10.5
15 hepatoportal sclerosis 10.5
16 immune deficiency disease 10.5
17 liver disease 10.5
18 common variable immunodeficiency 10.4
19 systemic lupus erythematosus 10.4
20 pulmonary hypertension 10.4
21 vascular disease 10.4
22 hypersplenism 10.4
23 lupus erythematosus 10.4
24 encephalopathy 10.4
25 hepatic coma 10.4
26 hepatic encephalopathy 10.4
27 adenoma 10.4
28 peliosis hepatis 10.4
29 thrombophilia due to thrombin defect 10.3
30 hepatocellular carcinoma 10.3
31 celiac disease 1 10.3
32 crest syndrome 10.3
33 portal vein thrombosis 10.3
34 telangiectasis 10.3
35 thrombocytopenia 10.3
36 banti's syndrome 10.3
37 scleroderma, familial progressive 10.3
38 hepatocellular adenoma 10.3
39 glomerulonephritis 10.3
40 antiphospholipid syndrome 10.3
41 vasculitis 10.3
42 polyarteritis nodosa 10.3
43 splenic artery aneurysm 10.2
44 myeloproliferative neoplasm 10.2
45 systemic mastocytosis 10.2
46 mastocytosis 10.2
47 congenital hepatic fibrosis 10.2
48 pulmonary hypertension, primary, 1 10.2
49 neutropenia 10.2
50 autoimmune hepatitis 10.2

Graphical network of the top 20 diseases related to Nodular Regenerative Hyperplasia:



Diseases related to Nodular Regenerative Hyperplasia

Symptoms & Phenotypes for Nodular Regenerative Hyperplasia

Human phenotypes related to Nodular Regenerative Hyperplasia:

58 31
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 portal hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0001409
2 abnormality of the hepatic vasculature 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Nodular Regenerative Hyperplasia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.02 EFNB2 F3 GFER ITPA JAG1 NOTCH1
2 cellular MP:0005384 9.95 EFNB2 F3 GFER ITPA JAG1 NOTCH1
3 hematopoietic system MP:0005397 9.92 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
4 cardiovascular system MP:0005385 9.91 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
5 mortality/aging MP:0010768 9.81 EFNB2 F3 GFER ITPA JAG1 NOTCH1
6 integument MP:0010771 9.73 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
7 muscle MP:0005369 9.43 EFNB2 F3 ITPA JAG1 NOTCH1 NOTCH2
8 respiratory system MP:0005388 9.02 EFNB2 F3 ITPA NOTCH1 NOTCH2

Drugs & Therapeutics for Nodular Regenerative Hyperplasia

Drugs for Nodular Regenerative Hyperplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caffeine Approved Phase 4 58-08-2 2519
2
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
3 Anti-Inflammatory Agents Phase 4
4 Analgesics, Non-Narcotic Phase 4
5 Anti-Inflammatory Agents, Non-Steroidal Phase 4
6 Mesalamine Phase 4 89-57-6
7 Calcium, Dietary Phase 4
8 Analgesics Phase 4
9 Calcium Supplement Phase 4
10
Propranolol Approved, Investigational Phase 3 525-66-6 4946
11
Apixaban Approved Phase 3 503612-47-3 10182969
12 Neurotransmitter Agents Phase 3
13 Anti-Arrhythmia Agents Phase 3
14 Adrenergic Antagonists Phase 3
15 Antihypertensive Agents Phase 3
16 Adrenergic beta-Antagonists Phase 3
17 Vasodilator Agents Phase 3
18 Adrenergic Agents Phase 3
19 Liver Extracts Phase 3
20
protease inhibitors Phase 3
21 Antithrombins Phase 3
22 HIV Protease Inhibitors Phase 3
23 Serine Proteinase Inhibitors Phase 3
24 Anticoagulants Phase 3
25 Antithrombin III Phase 3
26 Factor Xa Inhibitors Phase 3
27
Serine Investigational, Nutraceutical Phase 3 56-45-1 5951
28
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
29
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
30
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
31
Busulfan Approved, Investigational Phase 1, Phase 2 55-98-1 2478
32
alemtuzumab Approved, Investigational Phase 1, Phase 2 216503-57-0
33 Pharmaceutical Solutions Phase 1, Phase 2
34 Antirheumatic Agents Phase 1, Phase 2
35 Antibodies, Monoclonal Phase 1, Phase 2
36 Alkylating Agents Phase 1, Phase 2
37 Anti-Infective Agents Phase 1, Phase 2
38 Antibiotics, Antitubercular Phase 1, Phase 2
39 Antifungal Agents Phase 1, Phase 2
40 Anti-Bacterial Agents Phase 1, Phase 2
41 Immunosuppressive Agents Phase 1, Phase 2
42 Immunologic Factors Phase 1, Phase 2
43 Immunoglobulins Phase 1, Phase 2
44 Antibodies Phase 1, Phase 2
45
Norethindrone Approved 68-22-4 6230
46
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
47
Polyestradiol phosphate Approved 28014-46-2
48
Epinephrine Approved, Vet_approved 51-43-4 5816
49
Racepinephrine Approved 329-65-7 838
50
Etomidate Approved 33125-97-2 36339 667484

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 CLINICAL MANAGEMENT OF CHILDHOOD INTESTINAL LYMPHOID NODULAR HYPERPLASIA: A RANDOMIZED CONTROLLED CLINICAL TRIAL. Unknown status NCT01789294 Phase 4 Mesalamine
2 Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial Completed NCT01000779 Phase 3 Propranolol
3 Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension Recruiting NCT04007289 Phase 3 Apixaban;Placebo
4 Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist® in Healthy Volunteers and in Patients With Liver Disease Completed NCT01420211 Phase 1, Phase 2 Primovist® 0,25 mmol/ml solution for injection
5 High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease Recruiting NCT02629120 Phase 1, Phase 2 Campath;Busulfan IV;Sirolimus;cyclophosphamide
6 Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection Unknown status NCT03208192
7 Evaluation of Gastroesophageal Varices in Cirrhotic and Non-cirrhotic Patients With Portal Hypertension by Transnasal Endoscopy. Unknown status NCT02767206
8 Prevalence of Mutations of Glucocorticoid Receptors in Bilateral Adrenal Hyperplasia Unknown status NCT02810496
9 Contrast Enhanced Ultrasound for the Evaluation of Focal Liver Lesions - a Multi-center Study on the Usefulness in the Clinical Practice Unknown status NCT01329458
10 Exploratory Phase IV Randomized Single Blind Study Evaluating the Efficacy and Tolerability of Hemopatch in Improving Time of Hemostasis and Preventing Post-operative Complications After Hepatic Resection Unknown status NCT03323359
11 Diagnostic Accuracy of 18F-FluoroethylCholine Positron Emission Tomography for Hepatocellular Carcinoma Unknown status NCT02238769
12 Feasibility of Electromagnetic Acoustic Imaging of Liver Tumours - A Pilot Study Unknown status NCT02827786
13 Quantitative Liver Functions in Turner Syndrome With and Without Hormone Replacement Therapy Completed NCT00825617 Hormone replacement therapy
14 Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension Completed NCT02635815
15 "The Fingerprint: Spoke-wheel Sign" of Focal Nodular Hyperplasia: Assessment of Novel Ultrasound Approach Using Superb Microvascular Imaging Technique Completed NCT02737865 Sonazoid
16 Quantitative Real-time Ultrasound Elastography (Shear Wave Elastography - SWE™) for Characterisation of Liver Tumors Completed NCT02156700
17 Agreement Among Expert Radiologists in Diagnosing Primary Liver Tumors by Magnetic Resonance Imaging (MRI) in Non-Cirrhotic Patients - A Double Blind International Multicenter Study Completed NCT01234701
18 Evaluation of Sickle Cell Liver Disease Completed NCT01950429
19 Functional Imaging With 11C-Metomidate Positron Emission Tomography Versus Adrenal Vein Sampling in Differential Diagnosis of Unilateral and Bilateral Aldosterone Secretion in Primary Aldosteronism Completed NCT01567111
20 Characterization of Liver Masses With Contrast Enhanced Ultrasound (CEUS): A Comparison With Standard Institutional Contrast Enhanced CT (CECT) or MR Scan (CEMRI) Completed NCT00828607
21 Studies of Immune Regulation in Patients With Common Variable Immunodeficiency and Related Humoral Immunodeficiency Syndromes Recruiting NCT00001244
22 The Impact of Sarcopenia, Body Composition and Other Biometric Parameters on the Postoperative Outcomes of Patients Undergoing Liver Resection for Different Indications Recruiting NCT03630978
23 Vascular Liver Disease Evaluation, Follow Up and Non-Invasive Diagnostics Program Recruiting NCT03717792
24 Evaluation of the Efficacy of Contrast Enhanced Ultrasound Compared to MRI for Differentiation of Hepatic Lesions Recruiting NCT03652636
25 International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158
26 Advanced Magnetic Resonance Technics for the Assessment of Liver Function Before and After Transjugular Intrahepatic Portosystemic Shunt Recruiting NCT03933891
27 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Active, not recruiting NCT00565903

Search NIH Clinical Center for Nodular Regenerative Hyperplasia

Genetic Tests for Nodular Regenerative Hyperplasia

Anatomical Context for Nodular Regenerative Hyperplasia

MalaCards organs/tissues related to Nodular Regenerative Hyperplasia:

40
Liver, Bone, Bone Marrow, Kidney, Testes, Spleen, T Cells

Publications for Nodular Regenerative Hyperplasia

Articles related to Nodular Regenerative Hyperplasia:

(show top 50) (show all 596)
# Title Authors PMID Year
1
Drug-induced nodular regenerative hyperplasia. 61 52
24879987 2014
2
Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension. 61 52
22554152 2012
3
Hepatocellular adenoma(s) arising in nodular regenerative hyperplasia in a patient with systemic lupus erythematosus. 61
31810588 2020
4
Liver stiffness measurement in patients with nodular regenerative hyperplasia undergoing magnetic resonance elastography. 61
31834457 2020
5
Nodular Regenerative Hyperplasia Associated With Primary Liver Malignancies. 61
31429968 2020
6
Liver Transplantation for Decompensated Cirrhosis Secondary to Telomerase Reverse Transcriptase (TERT) Mutation. 61
31943309 2020
7
Aberrant von Willebrand Factor Expression of Sinusoidal Endothelial Cells and Quiescence of Hepatic Stellate Cells in Nodular Regenerative Hyperplasia and Obliterative Portal Venopathy. 61
31994248 2020
8
Abernethy malformation and hepatocellular carcinoma: a serious consequence of a rare disease. 61
31911408 2020
9
Recurrent metastatic breast cancer presenting with portal hypertension and pseudocirrhosis. 61
31767605 2019
10
Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It. 61
31771307 2019
11
[Unknown liver lesions]. 61
31752038 2019
12
Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis. 61
30625404 2019
13
Budd-Chiari Syndrome in a Patient With Simultaneous Diagnosis of Hepatic Sarcoidosis and Nodular Regenerative Hyperplasia. 61
31750374 2019
14
Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review. 61
30462857 2019
15
Paraneoplastic nodular regenerative hyperplasia of the liver associated with placental site trophoblastic tumor. 61
31193692 2019
16
Clinicopathologic characteristics of de novo nodular regenerative hyperplasia in pediatric liver transplant. 61
31124197 2019
17
Nodular Regenerative Hyperplasia: Expression Pattern of Glutamine Synthetase and a Potential Role for Hepatic Progenitor Cells. 61
31335486 2019
18
Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies. 61
31094013 2019
19
Letter to the Editor: Is Nodular Regenerative Hyperplasia an Immune-Mediated Phenomenon? 61
30820967 2019
20
The Spectrum of Hepatic Involvement in Patients With Telomere Disease. 61
30791107 2019
21
Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients. 61
31203688 2019
22
Novel IL2RG Mutation Causes Leaky TLOWB+NK+ SCID With Nodular Regenerative Hyperplasia and Normal IL-15 STAT5 Phosphorylation. 61
29939941 2019
23
Successful treatment of noncirrhotic portal hypertension with eculizumab in paroxysmal nocturnal hemoglobinuria: A case report. 61
31183008 2019
24
Porto-sinusoidal vascular disease: proposal and description of a novel entity. 61
30957754 2019
25
A case of incontinentia pigmenti associated with congenital absence of portal vein system and nodular regenerative hyperplasia. 61
30328117 2019
26
Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients. 61
29775790 2019
27
Mycobacterium chimaera Hepatitis: A New Disease Entity. 61
30346305 2019
28
Idiopathic portal hypertension presenting with hepatic nodular regenerative hyperplasia after splenectomy: a case report. 61
31933916 2019
29
The Utility of MR Elastography to Differentiate Nodular Regenerative Hyperplasia from Cirrhosis. 61
30014488 2019
30
Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: A systematic review. 61
31125338 2019
31
Portal vein thrombosis leading to pre-sinusoidal non-cirrhotic portal hypertension resulting in decreased synthetic function of the liver. 61
31191844 2019
32
A Novel CD3G Mutation in a Taiwanese Patient With Normal T Regulatory Function Presenting With the CVID Phenotype Free of Autoimmunity-Analysis of all Genotypes and Phenotypes. 61
31921117 2019
33
Common Variable Immunodeficiency and Liver Involvement. 61
28785926 2018
34
Heterogeneity of Fibrosis in Liver Biopsies of Patients With Heart Failure Undergoing Heart Transplant Evaluation. 61
30273196 2018
35
Liver Stiffness Measurements in Patients with Noncirrhotic Portal Hypertension-The Devil Is in the Details. 61
30014586 2018
36
Nodular Regenerative Hyperplasia Associated With Immune Checkpoint Blockade. 61
30014512 2018
37
Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine? 61
30600283 2018
38
Liver atoll sign: Nodular regenerative hyperplasia. 61
30309113 2018
39
Liver atoll sign: Nodular regenerative hyperplasia. 61
30309139 2018
40
Nodular regenerative hyperplasia in inflammatory bowel disease patients with allopurinol-thiopurine cotherapy. 61
30063483 2018
41
Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases. 61
30093084 2018
42
Hepatotoxicity of Inflammatory Bowel Disease Medications. 61
30036242 2018
43
Hepatic manifestations of telomere biology disorders. 61
29758336 2018
44
Hepatocellular nodules in vascular liver diseases. 61
29804132 2018
45
Portal Vein Thrombosis: Imaging the Spectrum of Disease With an Emphasis on MRI Features. 61
29792748 2018
46
Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. 61
29246416 2018
47
Isolated hepatic non-obstructive sinusoidal dilatation, 20-year single center experience. 61
29844855 2018
48
Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome. 61
29156507 2018
49
Nodular Regenerative Hyperplasia of the Liver: A Rare Vascular Complication in Systemic Sclerosis. 61
29093156 2018
50
Refractory Hepatic Hydrothorax: A Rare Complication of Systemic Sclerosis and Presinusoidal Portal Hypertension. 61
29854501 2018

Variations for Nodular Regenerative Hyperplasia

Expression for Nodular Regenerative Hyperplasia

Search GEO for disease gene expression data for Nodular Regenerative Hyperplasia.

Pathways for Nodular Regenerative Hyperplasia

Pathways related to Nodular Regenerative Hyperplasia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.24 NOTCH2 NOTCH1 JAG1
2
Show member pathways
12.19 NOTCH2 NOTCH1 JAG1
3 11.84 NOTCH2 NOTCH1 JAG1
4
Show member pathways
11.59 NOTCH2 NOTCH1 JAG1
5 11.2 PCNA NOTCH1 JAG1
6 11.16 NOTCH1 JAG1
7 11.02 NOTCH2 NOTCH1
8 10.97 NOTCH2 NOTCH1 JAG1 F3 EFNB2
9 10.93 NOTCH2 NOTCH1
10 10.86 TPMT ITPA
11 10.62 NOTCH1 JAG1
12 10.56 NOTCH2 NOTCH1 JAG1
13 10.55 NOTCH1 JAG1

GO Terms for Nodular Regenerative Hyperplasia

Cellular components related to Nodular Regenerative Hyperplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adherens junction GO:0005912 8.8 NOTCH1 JAG1 EFNB2

Biological processes related to Nodular Regenerative Hyperplasia according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 animal organ morphogenesis GO:0009887 9.76 NOTCH2 JAG1 EFNB2
2 Notch signaling pathway GO:0007219 9.71 NOTCH2 NOTCH1 JAG1
3 negative regulation of neuron differentiation GO:0045665 9.65 NOTCH1 JAG1
4 heart looping GO:0001947 9.65 NOTCH2 NOTCH1
5 negative regulation of cell differentiation GO:0045596 9.64 NOTCH1 JAG1
6 embryonic limb morphogenesis GO:0030326 9.64 NOTCH2 NOTCH1
7 humoral immune response GO:0006959 9.63 NOTCH2 NOTCH1
8 keratinocyte differentiation GO:0030216 9.63 NOTCH1 JAG1
9 positive regulation of Notch signaling pathway GO:0045747 9.62 NOTCH1 JAG1
10 positive regulation of BMP signaling pathway GO:0030513 9.62 NOTCH2 NOTCH1
11 positive regulation of Ras protein signal transduction GO:0046579 9.61 NOTCH2 NOTCH1
12 aortic valve morphogenesis GO:0003180 9.61 NOTCH1 JAG1
13 neuronal stem cell population maintenance GO:0097150 9.6 NOTCH1 JAG1
14 cell fate determination GO:0001709 9.59 NOTCH2 JAG1
15 inflammatory response to antigenic stimulus GO:0002437 9.58 NOTCH2 NOTCH1
16 negative regulation of stem cell differentiation GO:2000737 9.57 NOTCH1 JAG1
17 left/right axis specification GO:0070986 9.56 NOTCH2 NOTCH1
18 cardiac septum morphogenesis GO:0060411 9.55 NOTCH1 JAG1
19 response to muramyl dipeptide GO:0032495 9.52 NOTCH1 JAG1
20 morphogenesis of an epithelial sheet GO:0002011 9.51 NOTCH2 JAG1
21 glomerular visceral epithelial cell development GO:0072015 9.49 NOTCH2 JAG1
22 interleukin-4 secretion GO:0072602 9.48 NOTCH2 NOTCH1
23 venous blood vessel morphogenesis GO:0048845 9.46 NOTCH1 EFNB2
24 ciliary body morphogenesis GO:0061073 9.43 NOTCH2 JAG1
25 regulation of developmental process GO:0050793 9.4 NOTCH2 NOTCH1
26 distal tubule development GO:0072017 9.37 NOTCH1 JAG1
27 negative regulation of growth rate GO:0045967 9.32 NOTCH2 NOTCH1
28 positive regulation of aorta morphogenesis GO:1903849 9.26 NOTCH1 EFNB2
29 positive regulation of cardiac epithelial to mesenchymal transition GO:0062043 9.16 NOTCH1 JAG1
30 pulmonary valve morphogenesis GO:0003184 9.13 NOTCH2 NOTCH1 JAG1
31 Notch signaling involved in heart development GO:0061314 8.8 NOTCH2 NOTCH1 JAG1

Molecular functions related to Nodular Regenerative Hyperplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Notch binding GO:0005112 8.62 NOTCH1 JAG1

Sources for Nodular Regenerative Hyperplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....